Indivior Pharmaceuticals (NASDAQ:INDV) affirms FY2026 sales outlook from $1.295 billion-$1.365 billi

Indivior (NASDAQ:INDV) reported quarterly earnings of $1.32 per share which beat the analyst consens

Q3'26 Total Net Revenue of $ 356 Million, Up 13% YoY Record Quarterly Total SUBLOCADE® Net Revenue o

Barclays analyst Glen Santangelo maintains Indivior Pharmaceuticals (NASDAQ:INDV) with a Overweig

Indivior (NASDAQ: INDV - Get Free Report) is expected to be posting its Q3 2026 results before the m

RICHMOND, Va., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today

Shares of Indivior PLC (NASDAQ: INDV - Get Free Report) have received a consensus rating of "Buy" fr

Sonoma Pharmaceuticals (NASDAQ: SNOA - Get Free Report) and Indivior (NASDAQ: INDV - Get Free Report

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti,

RICHMOND, Va., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) (“In

INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed

HighTower Advisors LLC acquired a new stake in Indivior PLC (NASDAQ: INDV) during the second quarter

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Indivior Pharmaceutica

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merge

INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on Su

Indivior (NASDAQ:INDV) released second-quarter financial results and hosted an earnings call on Tues

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swic

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,

Barclays analyst Glen Santangelo maintains Indivior Pharmaceuticals (NASDAQ:INDV) with a Overweig

Indivior announces a merger with Supernus to form a CNS-focused biopharma company, tops Q2 earnings

The most oversold health care stocks present a buying opportunity. RSI indicator compares stock stre

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Indivior Pharmaceuticals,

NEW YORK, Aug. 3, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Asso

Supernus Pharmaceuticals (SUPN) has seen its stock rise following the announcement of an all-stock m

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and Indivior Pharmaceuticals Inc. (NASDAQ:INDV) on Mond

Supernus and Indivior agree to merge in an all-stock deal, targeting $2.2 billion in revenue and $12

Indivior Pharmaceuticals (NASDAQ:INDV) raises FY2026 sales outlook from $1.215 billion-$1.285 billio

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today

Barclays analyst Glen Santangelo initiates coverage on Indivior Pharmaceuticals (NASDAQ:INDV) wit

Compared to patients adherent to monthly injectable buprenorphine, patients on other MOUD (adherent

Indivior Pharmaceuticals, Inc. (NASDAQ:INDV), today announced that it has entered into a $175 millio

Indivior Pharmaceuticals (NASDAQ:INDV) raises FY2026 sales outlook from $1.125 billion-$1.195 billio

Indivior (NASDAQ:INDV) reported quarterly earnings of $0.96 per share which beat the analyst consens

https://sam.gov/opp/301d35fe03404ac6ad3aec2215c3c893/view

Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced its intention to offer, subject to mar

Patients adherent to SUBLOCADE® for 12 months had 42% lower adjusted non-MOUD medical costs vs. thos

Indivior Pharmaceuticals (NASDAQ:INDV) affirms FY2026 sales outlook from $1.125 billion-$1.195 billi

Indivior (NASDAQ:INDV) reported quarterly earnings of $0.82 per share which beat the analyst consens

Kevin Mahn highlighted the potential impact of the recent tariff noise on the market and advised inv

HC Wainwright & Co. analyst Brandon Folkes maintains Indivior (NASDAQ:INDV) with a Buy and ra

Both monthly maintenance doses (100 mg and 300 mg) improved opioid abstinence and were well-tolerate

https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20251205-1480992/1480992_decembe

Indivior PLC (Nasdaq: INDV) presented three new scientific posters at the Academy of Managed Care Ph

Piper Sandler analyst David Amsellem reiterates Indivior (NASDAQ:INDV) with a Overweight and rais

HC Wainwright & Co. analyst Brandon Folkes maintains Indivior (NASDAQ:INDV) with a Buy and ra